Baron Opportunity Fund Retail Shs (BIOPX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.00: the stock has moved roughly in step with the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBaron Opportunity Fund Retail Shs (BIOPX) trades at $60.87. Baron Opportunity Fund is a U.S. based fund focused on high growth businesses. Sector: Unknown.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for BIOPX: BIOPX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIOPX against Unknown peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Baron Opportunity Fund Retail Shs (BIOPX) Business Overview & Investment Profile
Baron Opportunity Fund strategically invests in U.S. high-growth businesses across various market capitalizations and sectors, aiming for substantial capital appreciation through equity securities. The fund's adaptability to innovations and technological advancements positions it uniquely within the investment landscape, focusing on long-term growth opportunities.
What Is the Investment Thesis for BIOPX?
Baron Opportunity Fund's investment thesis centers on identifying and capitalizing on high-growth potential within the U.S. equity market. The fund's ability to invest across all market capitalizations and sectors provides a broad universe of potential investments. Key to the fund's success is its focus on companies that are expected to benefit from technological innovations. The fund's performance is closely tied to the overall health of the U.S. economy and the performance of the equity markets. A potential risk lies in the fund's broad mandate, which requires careful stock selection to avoid over-diversification or investments in sectors that may underperform. The fund's beta of 1.00 suggests that it is expected to move in line with the overall market.
Based on FMP financials and quantitative analysis
BIOPX Key Highlights
Invests primarily in equity securities of U.S. high growth businesses.
- Focuses on companies of any market capitalization.
- Targets companies that will benefit from innovations and advances in technology.
- Aims for capital appreciation as its primary investment objective.
- The fund has a beta of 1.00, indicating market-average volatility.
What Are BIOPX's Key Strengths?
Flexibility to invest across all market capitalizations and sectors.
- Focus on identifying companies that will benefit from technological innovations.
- Experienced investment team.
- Long-term investment horizon.
What Are BIOPX's Weaknesses?
Broad mandate requires careful stock selection.
- Performance is tied to the overall health of the U.S. economy.
- Potential for over-diversification.
What Could Drive BIOPX Stock Higher?
Positive earnings reports from key portfolio holdings.
- Continued innovation and technological advancements in portfolio companies.
- Favorable macroeconomic conditions in the U.S.
What Are the Key Risks for BIOPX?
Economic recession or market downturn.
- Increased competition in the investment management industry.
- Changes in government regulations.
- Technological disruptions that could negatively impact portfolio companies.
What Are the Growth Opportunities for BIOPX?
- Expansion into Emerging Technologies: The fund can capitalize on the rapid growth of emerging technologies such as artificial intelligence, blockchain, and renewable energy. By identifying and investing in companies that are at the forefront of these technologies, the fund can potentially generate significant returns. The market for these technologies is expected to grow exponentially over the next decade, presenting a substantial growth opportunity for the fund. Timeline: Ongoing.
- Increased Allocation to Small-Cap Companies: The fund's ability to invest in companies of any market capitalization allows it to increase its allocation to small-cap companies that have the potential for rapid growth. Small-cap companies often offer higher growth rates than large-cap companies, but they also come with higher risk. By carefully selecting small-cap companies with strong fundamentals and sustainable competitive advantages, the fund can potentially generate outsized returns. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: The fund can partner with other investment firms or industry experts to gain access to specialized knowledge and resources. These partnerships can help the fund identify promising investment opportunities and improve its due diligence process. Collaborations with technology companies can also provide the fund with insights into emerging trends and disruptive technologies. Timeline: Ongoing.
- Geographic Expansion within the U.S.: While the fund focuses on U.S. companies, it can explore opportunities in different regions of the country that are experiencing rapid economic growth. For example, the fund can increase its exposure to companies in the Sun Belt region, which is experiencing population growth and economic expansion. By diversifying its geographic exposure, the fund can reduce its overall risk and potentially enhance its returns. Timeline: Ongoing.
- Focus on Sustainable and Socially Responsible Investing: The fund can incorporate environmental, social, and governance (ESG) factors into its investment decision-making process. By investing in companies that are committed to sustainability and social responsibility, the fund can attract investors who are increasingly concerned about these issues. The market for sustainable and socially responsible investing is growing rapidly, presenting a significant growth opportunity for the fund. Timeline: Ongoing.
What Are BIOPX's Competitive Advantages?
- Flexibility to invest across all market capitalizations and sectors.
- Focus on identifying companies that will benefit from technological innovations.
- Experienced investment team with a proven track record.
- Long-term investment horizon.
What Does BIOPX Do?
Baron Opportunity Fund is designed to seek capital appreciation through investments in U.S. high-growth businesses. The fund primarily invests in equity securities, with a focus on common stock. The fund's strategy is not limited by market capitalization, allowing it to explore opportunities in companies of all sizes, from small-cap startups to large-cap corporations. A key aspect of the fund's approach is its flexibility regarding sector and industry. The Adviser has the discretion to invest in companies across any sector, provided they believe the company will benefit from innovations and advances in technology. This broad mandate enables the fund to capitalize on emerging trends and disruptive technologies, potentially leading to significant capital appreciation. The fund's investment decisions are driven by rigorous analysis and a focus on identifying companies with strong growth potential and sustainable competitive advantages. The fund's objective is long-term capital appreciation, making it suitable for investors with a long-term investment horizon.
What Products and Services Does BIOPX Offer?
- Invests in equity securities of U.S. high growth businesses.
- Focuses on common stock as the primary investment vehicle.
- Invests in companies of any market capitalization.
- Targets companies that will benefit from innovations and advances in technology.
- Seeks capital appreciation as its primary investment objective.
- Operates with a flexible approach across various sectors and industries.
How Does BIOPX Make Money?
- The fund generates revenue through capital appreciation of its investments.
- Management fees are charged based on the assets under management (AUM).
- The fund may also generate income from dividends, although the dividend yield is currently none.
- Investment decisions are driven by rigorous analysis and a focus on identifying companies with strong growth potential.
What Industry Does BIOPX Operate In?
Baron Opportunity Fund operates within the broader investment management industry, which is characterized by intense competition and evolving market dynamics. The fund's focus on high-growth businesses aligns with the increasing investor interest in companies that are leveraging technology and innovation to disrupt traditional industries. The fund's ability to invest across all sectors provides it with a competitive advantage in identifying emerging trends and capitalizing on growth opportunities. The performance of the fund is influenced by macroeconomic factors, such as interest rates, inflation, and economic growth, as well as market sentiment and investor risk appetite.
Who Are BIOPX's Key Customers?
- Individual investors seeking capital appreciation.
- Institutional investors looking for exposure to U.S. high-growth businesses.
- Retirement plans and endowments.
- High-net-worth individuals.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a fund, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 44 |
| 2026-08-26 | 44 |
| 2026-08-29 | 44 |
| 2026-09-01 | 44 |
| 2026-09-04 | 44 |
| 2026-09-07 | 44 |
| 2026-09-10 | 44 |
What changed?
The score has stayed at 44.
Over the same 18 days the stock moved +0.1%.
BIOPX Financials
Bull Case vs Bear Case
Bull Case
- Flexibility to invest across all market capitalizations and sectors.
- Focus on identifying companies that will benefit from technological innovations.
- Experienced investment team.
- Long-term investment horizon.
Bear Case
- Broad mandate requires careful stock selection.
- Performance is tied to the overall health of the U.S. economy.
- Potential for over-diversification.
- Potential: Economic recession or market downturn.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BIOPX Latest News
No recent news available for BIOPX.
BIOPX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIOPX.
Price Targets
Wall Street price target analysis for BIOPX.
BIOPX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIOPX; grades run from A+ (80-100) to F (below 30).
Classification
BIOPX Unknown Stock FAQ
Is BIOPX a good stock?
Stock Expert AI does not rate BIOPX buy, sell or hold. Baron Opportunity Fund Retail Shs has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for BIOPX?
The main risks for Baron Opportunity Fund include market risk, which is the risk that the overall stock market will decline, negatively impacting the fund's performance.
What are the key factors to evaluate for BIOPX?
Evaluate BIOPX on fundamentals, analyst consensus, and risk factors. Key to the fund's success is its focus on companies that are expected to benefit from technological innovations. Not financial advice.
How frequently does BIOPX data refresh on this page?
BIOPX's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BIOPX's recent stock price performance?
Baron Opportunity Fund Retail Shs (BIOPX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Flexibility to invest across all market capitalizations and sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOPX overvalued or undervalued right now?
Baron Opportunity Fund Retail Shs (BIOPX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BIOPX?
Yes, most major brokerages offer fractional shares of Baron Opportunity Fund Retail Shs (BIOPX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BIOPX's earnings and financial reports?
Baron Opportunity Fund Retail Shs (BIOPX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BIOPX earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.